A phthalimide-triazole derivative obtained by click chemistry exhibits trypanocidal activity, induces autophagy and ameliorates Trypanosoma cruzi infection
- PMID: 40101588
- DOI: 10.1016/j.biopha.2025.117963
A phthalimide-triazole derivative obtained by click chemistry exhibits trypanocidal activity, induces autophagy and ameliorates Trypanosoma cruzi infection
Abstract
Chagas disease (CD), caused by Trypanosoma cruzi, remains a leading cause of cardiomyopathy and heart failure in Latin America. Since the 1970s, benznidazole (BNZ) and nifurtimox (NFX) have been the only chemotherapeutic agents used to treat CD. However, their toxicity and low effectiveness in the chronic phase of the disease, make the development of more efficient chemotherapeutics imperative. Here, we investigated the effects of 1,2,3-triazole hybrids, synthesized via click chemistry, containing either phthalimide (FT1, FT2, FT3, FT4) or naphthoquinone (NT1) moieties on T. cruzi and their cytotoxicity on mammalian cells. NT1 and FT1 were the most effective against intracellular parasite with an IC50 = 31.1 and 189.2 µM, respectively. FT1-FT4 showed low cytotoxicity to mammalian cells (CC50 > 754 µM), while NT1 exhibited moderate toxicity (CC50 ≥ 96.1 µM). FT1 demonstrated the highest selectivity towards trypomastigotes and amastigotes with selectivity indexes (SeI) of 6.9 and 6.7, respectively. Ultrastructural analysis of trypomastigotes treated with FT1 revealed mitochondrial alterations, lipid accumulation and Golgi complex disorganization. FT1 also decreased the mitochondrial membrane potential, increased mitochondrial reactive oxygen species (ROS) production, and induced late apoptosis in trypomastigotes. In infected cardiac cells, FT1 treatment led to degradation of amastigotes and Golgi disruption. An increase in autophagosomes in treated host cells and their interaction with intracellular parasites suggest that FT1-induced host cell autophagy may play a role in mitigating the infection and protecting cardiac cells from its deleterious effects.
Keywords: 1,2,3-Triazole; Autophagy; Chemotherapy; Click chemistry; Trypanosoma cruzi.
Copyright © 2025 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. Regina Celia Bressan Queiroz de Figueiredo reports financial support was provided by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). Lucas Eduardo Bezerra de Lima reports financial support was provided by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). Regina Celia Bressan Queiroz de Figueiredo has patent Phthalimide-triazole derivatives useful in the treatment of leishmaniasis, pharmaceutical composition, use of the pharmaceutical composition, and method of treating leishmaniasis pending to BR1020200265253. The authors Regina Celia Bressan Queiroz de Figueiredo, Vanderlan Nogueira Holanda and Ronaldo Nascimento de Oliveira have a patent application related to Leishmania treatment using FT1 and FT2. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical